Antimicrobial susceptibility testing of various concentrations of pcAgNPs and 1 mM AgNO3 toward a series of clinical isolates of bacteria after 24 h of treatmenta.
| Test strains | Antibiotics (25 μg mL−1) | Zone of inhibition (in mm) induced by pcAgNPs | AgNO3 | ||||
|---|---|---|---|---|---|---|---|
| 5 μg mL−1 | 15 μg mL−1 | 25 μg mL−1 | 50 μg mL−1 | ||||
| S. aureus (MRSA) | AN | 7.7 ± 0.58 | 12.8 ± 0.79 | 15.8 ± 0.62 | 19.1 ± 0.70 | 24 ± 0.82 | 10.5 ± 1.08 |
| TET | 9.3 ± 0.29 | ||||||
| VA | NZ | ||||||
| S. epidermidis (MRSE) | AN | 8.7 ± 0.26 | 11.7 ± 1.25 | 15.2 ± 0.59 | 18 ± 0.82 | 23 ± 2.16 | 10.7 ± 1.25 |
| TET | 9.8 ± 0.21 | ||||||
| VA | NZ | ||||||
| P. mirabilis | AN | 12.3 ± 0.76 | 10.8 ± 1.03 | 15.3 ± 1.25 | 18 ± 1.41 | 24.5 ± 1.23 | 13.5 ± 0.41 |
| FEP | 10.9 ± 0.36 | ||||||
| NET | 10.1 ± 0.51 | ||||||
| E. coli | AN | 12.7 ± 0.58 | 9.8 ± 0.85 | 14 ± 2.16 | 17.3 ± 0.94 | 22.5 ± 1.05 | 11.2 ± 0.85 |
| TET | 9.2 ± 0.59 | ||||||
| NET | 10.8 ± 0.35 | ||||||
| K. pneumoniae | AN | 11.2 ± 0.29 | 10.3 ± 0.47 | 15.7 ± 0.94 | 18.2 ± 0.57 | 24.2 ± 0.85 | 8.7 ± 0.47 |
| TET | 9.3 ± 0.31 | ||||||
| NET | 7.5 ± 0.87 | ||||||
| A. baumannii | AN | 11.5 ± 0.35 | 9.6 ± 0.42 | 14.7 ± 0.47 | 18.3 ± 0.47 | 23.7 ± 0.94 | 9.7 ± 0.38 |
| TET | 10.3 ± 0.29 | ||||||
| D | 7.6 ± 0.23 | ||||||
| Enterococcus sp. (VRE) | C | 10.3 ± 0.25 | 10 ± 0.82 | 16 ± 1.41 | 18.7 ± 0.94 | 22.1 ± 0.98 | 12.3 ± 0.47 |
| TET | 11.8 ± 0.75 | ||||||
| VA | 12 ± 0.15 | ||||||
a
AN – Amikacin; TET – Tetracycline; VA – Vancomycin; FEP – Cefepime; NET – Netilmicin; D – Doxycycline; C – Chloramphenicol; NZ – no zone. Data are representative of at least three independent experiments and expressed as mean ± standard deviation (SD) of the concentrations of Antibiotics and pcAgNPs.